Baidu
map

Cell:新分子逆转“衰老”,未发现任何明显副作用

2017-03-25 Chen 生物探索

Cell杂志上发表了一篇题为“Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging”的抗衰老突破进展。来自荷兰的一个科学家小组发现,定期注射一种肽分子能够选择性地找到并摧毁衰老细胞(senescent cell)。这一结果为改善自然衰老小鼠以及

Cell杂志上发表了一篇题为“Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging”的抗衰老突破进展。来自荷兰的一个科学家小组发现,定期注射一种肽分子能够选择性地找到并摧毁衰老细胞(senescent cell)。这一结果为改善自然衰老小鼠以及基因工程改造后快速衰老的小鼠的健康寿命(healthspan)提供了新的证据。

1 仅针对衰老细胞,无明显副作用

具体来说,该研究证明,这一对抗衰老细胞的分子能够逆转衰老相关的皮毛损失、肾功能受损以及虚弱(frailty)。研究中使用的这一分子的作用机制是:阻断了衰老相关蛋白FOXO4的一种能力,即告知另一种称为p53蛋白,不要让衰老细胞自我毁灭。通过干扰FOXO4-p53之间的作用,该肽分子能够引发衰老细胞凋亡或者自杀。

该研究的通讯作者Peter L.J. de Keizer说:“这一肽只有在衰老细胞中会导致细胞死亡。我们连续用这一分子处理小鼠超过10个月的时间,每周注射3次,没有发现任何明显的副作用。FOXO4在非衰老细胞中几乎不表达。”



在处理的不同时期,研究人员观察到了不同的结果:1)处理10天后,快速衰老(Fast-aging)的小鼠开始修复它们的皮毛;2) 处理约3周后,健康益处开始显现,接受处理的年老小鼠跑步的距离是未接受处理的对照组小鼠的两倍;3)处理一个月后,衰老小鼠中指示健康肾功能的标记增加了。



2 Science评论:杀死衰老细胞的新分子

该研究发表后,Science、BBC等网站均对其进行了报道。《科学》网站题为“Molecule kills elderly cells, reduces signs of aging in mice”的报道称,这一化合物使得年老的小鼠行动和表现上更加年轻,有望在人类中带来相同的作用。

随着年龄的增长,衰老细胞会在我们的组织中积累,研究者们认为,这些衰老细胞造成了心脏病、关节炎、糖尿病等疾病。迄今为止,科学家们已经报道了至少7个称为senolytics的化合物。它们的作用是杀死衰老细胞。据悉,目前有一个相关的临床试验正在肾病患者中测试其中的2个药物。

然而,目前这些senolytic化合物,许多是属于抗癌药物,有一些缺点。它们能够杀死健康细胞或者触发副作用,如导致血小板数量下降。

事实上,当de Keizer带领的研究小组发现上述cell论文中所阐述的、不同的攻击衰老细胞的分子时,他们正在调查这些衰老细胞是如何“存活”的。理论上说,衰老细胞携带着损伤的DNA,应该会激发保护性蛋白p53发挥作用,导致衰老细胞死亡。但研究人员发现,一种称为FOXO4的蛋白能够阻止p53发挥它的作用。

接着,科学家们设计了一个肽分子,携带了缩短版的FOXO4片段。在体外实验中(培养皿),这一肽能够阻止FOXO4和 p53互相作用,促进衰老细胞“自杀”。此外,这一分子还能够区分出健康细胞。

随后,正如前文所说,研究人员将这一分子注射到快速衰老的突变小鼠中。这些小鼠的寿命约是正常小鼠的一半。仅几个月大时,它们的皮毛就开始脱落,肾脏开始出现问题,并且会变得行动迟缓。然而,肽分子处理增加了它们的皮毛密度,逆转了肾脏损伤,并延长了它们能够在转轮上跑的时间。此外,当研究者们在正常年老的小鼠中测试这一分子时,他们观察到了相似的画面:除了改善肾脏和皮毛,用肽处理还增强了小鼠探索周围环境的意愿。



3 是里程碑,但仍有局限性

加拿大蒙特利尔大学的分子生物学家Francis Rodier说:“这绝对抗衰老领域的一个里程碑进展。这是首次有人员证明,我们可以处理衰老细胞,但不带来任何明显的副作用。”

梅奥诊所的糖尿病研究者James Kirkland认为,这篇论文为靶向衰老细胞提供了一种新的可能,但肽这类分子有它们的局限性。因为消化系统会破坏它们,所以只能通过吸入给药或者注射给药——你不能只是简单地吃颗药丸。



4 应用到人类,需谨慎前行

虽然这一分子并未减少血小板数量,但杀死大量的衰老细胞仍可能会引发潜在致命的并发症。此外,衰老细胞能够促进伤口愈合,破坏它们可能会损伤这一能力。这也是为何de Keizer和他的团队计划谨慎地推进这一分子的研究。
De Keizer期望能够基于这些发现创办一家公司,但是短期内,他们希望能够确定这一分子在人类中的安全性。他们计划先确定这一分子能否杀死与衰老细胞共享一些相似之处的癌细胞。具体来说,他们计划在恶性胶质瘤患者中开展相关的安全性临床试验。如果这一化合物被证明是安全的,科学家们可以考虑测试这一肽分子对抗衰老相关疾病或衰老本身的能力。

原始出处:

Marjolein P. Baar, Renata M.C. Brandt, Diana A. Putavet, et al.Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.DOI: http://dx.doi.org/10.1016/j.cell.2017.02.031

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869826, encodeId=b9c218698265c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 01 20:55:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824228, encodeId=a625182422884, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Aug 24 10:55:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923241, encodeId=2b921923241a1, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Wed Apr 19 13:55:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960085, encodeId=d17e196008536, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 07 13:55:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190910, encodeId=dce919091038, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Thu Apr 27 00:37:57 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182723, encodeId=ae0b182e23fd, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRphX6mAPAojbd1zjUU3jveibex0RDicR9I5rBwIxA8nacoPyETu8PjR9PuosNeBhibYFcHtDF4Tsyd5/0, createdBy=9f9b1671661, createdName=詹鱼, createdTime=Sun Mar 26 02:27:26 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182681, encodeId=643218268188, content=看好这个研究前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sat Mar 25 21:39:55 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869826, encodeId=b9c218698265c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 01 20:55:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824228, encodeId=a625182422884, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Aug 24 10:55:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923241, encodeId=2b921923241a1, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Wed Apr 19 13:55:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960085, encodeId=d17e196008536, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 07 13:55:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190910, encodeId=dce919091038, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Thu Apr 27 00:37:57 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182723, encodeId=ae0b182e23fd, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRphX6mAPAojbd1zjUU3jveibex0RDicR9I5rBwIxA8nacoPyETu8PjR9PuosNeBhibYFcHtDF4Tsyd5/0, createdBy=9f9b1671661, createdName=詹鱼, createdTime=Sun Mar 26 02:27:26 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182681, encodeId=643218268188, content=看好这个研究前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sat Mar 25 21:39:55 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869826, encodeId=b9c218698265c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 01 20:55:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824228, encodeId=a625182422884, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Aug 24 10:55:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923241, encodeId=2b921923241a1, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Wed Apr 19 13:55:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960085, encodeId=d17e196008536, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 07 13:55:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190910, encodeId=dce919091038, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Thu Apr 27 00:37:57 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182723, encodeId=ae0b182e23fd, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRphX6mAPAojbd1zjUU3jveibex0RDicR9I5rBwIxA8nacoPyETu8PjR9PuosNeBhibYFcHtDF4Tsyd5/0, createdBy=9f9b1671661, createdName=詹鱼, createdTime=Sun Mar 26 02:27:26 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182681, encodeId=643218268188, content=看好这个研究前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sat Mar 25 21:39:55 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1869826, encodeId=b9c218698265c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 01 20:55:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824228, encodeId=a625182422884, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Aug 24 10:55:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923241, encodeId=2b921923241a1, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Wed Apr 19 13:55:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960085, encodeId=d17e196008536, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 07 13:55:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190910, encodeId=dce919091038, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Thu Apr 27 00:37:57 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182723, encodeId=ae0b182e23fd, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRphX6mAPAojbd1zjUU3jveibex0RDicR9I5rBwIxA8nacoPyETu8PjR9PuosNeBhibYFcHtDF4Tsyd5/0, createdBy=9f9b1671661, createdName=詹鱼, createdTime=Sun Mar 26 02:27:26 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182681, encodeId=643218268188, content=看好这个研究前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sat Mar 25 21:39:55 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
    2018-02-07 维他命
  5. [GetPortalCommentsPageByObjectIdResponse(id=1869826, encodeId=b9c218698265c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 01 20:55:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824228, encodeId=a625182422884, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Aug 24 10:55:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923241, encodeId=2b921923241a1, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Wed Apr 19 13:55:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960085, encodeId=d17e196008536, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 07 13:55:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190910, encodeId=dce919091038, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Thu Apr 27 00:37:57 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182723, encodeId=ae0b182e23fd, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRphX6mAPAojbd1zjUU3jveibex0RDicR9I5rBwIxA8nacoPyETu8PjR9PuosNeBhibYFcHtDF4Tsyd5/0, createdBy=9f9b1671661, createdName=詹鱼, createdTime=Sun Mar 26 02:27:26 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182681, encodeId=643218268188, content=看好这个研究前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sat Mar 25 21:39:55 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
    2017-04-27 1881e9c2b1m

    不错,学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1869826, encodeId=b9c218698265c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 01 20:55:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824228, encodeId=a625182422884, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Aug 24 10:55:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923241, encodeId=2b921923241a1, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Wed Apr 19 13:55:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960085, encodeId=d17e196008536, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 07 13:55:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190910, encodeId=dce919091038, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Thu Apr 27 00:37:57 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182723, encodeId=ae0b182e23fd, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRphX6mAPAojbd1zjUU3jveibex0RDicR9I5rBwIxA8nacoPyETu8PjR9PuosNeBhibYFcHtDF4Tsyd5/0, createdBy=9f9b1671661, createdName=詹鱼, createdTime=Sun Mar 26 02:27:26 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182681, encodeId=643218268188, content=看好这个研究前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sat Mar 25 21:39:55 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
    2017-03-26 詹鱼

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1869826, encodeId=b9c218698265c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 01 20:55:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824228, encodeId=a625182422884, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Aug 24 10:55:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923241, encodeId=2b921923241a1, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Wed Apr 19 13:55:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960085, encodeId=d17e196008536, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 07 13:55:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190910, encodeId=dce919091038, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Thu Apr 27 00:37:57 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182723, encodeId=ae0b182e23fd, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRphX6mAPAojbd1zjUU3jveibex0RDicR9I5rBwIxA8nacoPyETu8PjR9PuosNeBhibYFcHtDF4Tsyd5/0, createdBy=9f9b1671661, createdName=詹鱼, createdTime=Sun Mar 26 02:27:26 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182681, encodeId=643218268188, content=看好这个研究前景, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Sat Mar 25 21:39:55 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
    2017-03-25 1881e9c2b1m

    看好这个研究前景

    0

相关资讯

Nature:自噬维持干细胞年轻,可能是“返老还童”的新希望

美国加州大学旧金山分校(UCSF)的一项新研究发现了血液和免疫系统老化的关键因素,为减缓甚至逆转越来越严重的老年疾病风险带来了希望,包括慢性炎症疾病、贫血、血癌、以及威胁生命的感染。关键在于一小部分干细胞(这些细胞在发育早期出现,负责在整个生命周期中更新血液)的健康状况与自噬作用(一种细胞的程序性死亡)之间的联系。这项研究发表在近日的《Nature》上,UCSF的团队发现,除了清理细胞中的废物之外

The Journals of Gerontology:两种“神药”白藜芦醇、二甲双胍或可对抗神经衰老

两种“神药”白藜芦醇和二甲双胍再刷存在感!近日,来自弗吉尼亚理工学院的一项研究表明,这两种物质或许可以抵抗神经衰老带来的不利影响。

Cell Metab:你知道哪种类型的运动最有助于延缓衰老吗?

运动好处多多,但这背后的分子生物学机制仍然不为人知。近日,一项发表于Cell Metabolism上的研究表明,高强度间歇训练(HIIT),如骑自行车和步行,能够促进细胞为线粒体和核糖体生产更多的蛋白质,从而有效地在细胞水平上延缓衰老。

Nat Commun:衰老新机制!RNA 质量控制

“最是人间留不住,朱颜辞镜花辞树。”衰老可谓是世上最无可奈何的事情了。虽然科学家们一直在努力了解衰老的过程,以期对抗衰老相关的疾病和保持长寿。但至今人们对衰老的本质及其内在的机制仍是知之甚少。近日,韩国浦项科技大学生命科学系的 Seung-Jae V. Lee 教授与基础科学研究所植物衰老研究中心的 Hong Gil Nam 教授合作,发现 RNA 的质量控制能够影响衰老过程。这一重大发现发表在《

衰老血液可再次年轻

来自年轻人的血液具有治愈衰老的疗效,那么人们是否可以不通过捐助者获得年轻血液呢?一种新发现的可让造血干细胞保持年轻的蛋白或许可以提供帮助。

深度长文:如何放慢衰老的脚步?

衰老是人类永恒的话题。几百年前,在炼金术士们还在疯狂研究点金石的年代,人们就开始尝试制造长生不老药。如今,随着医学科技的发展,人类的平均寿命在过去几个世纪得到了显着延长。这无疑让人类对青春、健康与长寿的渴望变得更为强烈。最近,美国化学会旗下的知名学术期刊《C&EN》刊登了一篇关于衰老与长寿的深度文章。在文章中,科学家们探讨了目前关于衰老机制的认识,以及一些潜在能延年益寿的方法。有一点我

Baidu
map
Baidu
map
Baidu
map